ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01274039
Recruitment Status : Completed
First Posted : January 11, 2011
Last Update Posted : April 15, 2013
Sponsor:
Information provided by:
University of Cologne

Brief Summary:
Local therapy for glaucoma is known to induce a conjunctival inflammation. Because of this, trabeculectomy is more likely to fail. The investigators exchange the local therapy by systemic therapy using acetazolamide and measure the eye pressure using local therapy and systemic therapy using acetazolamide. The investigators suspect an elevated eye pressure using acetazolamide compared to local therapy. In summary acetazolamide could be a better choice in reference to conjunctival inflammation, but a worse choice in reference to controlling eye pressure.

Condition or disease Intervention/treatment
Control of Elevated Eye Pressure by Local and Systemic Therapy Drug: Acetazolamide for glaucoma patients to lower eye pressure

Study Type : Observational
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide. A Possible Pretreatment for Trabeculectomy Surgery.
Study Start Date : February 2009
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Patient with a trabeculectomy planed Drug: Acetazolamide for glaucoma patients to lower eye pressure
Acetazolamide tablets 3 times daily for 3 to 4 weeks



Primary Outcome Measures :
  1. Eye pressure [ Time Frame: Once at the beginning of the study and once 3 to 4 weeks later ]
    The eye pressure is measured at the beginning of the study, when the patient is using the maximal tolerated local therapy and 3 to 4 weeks later, when using systemic acetazolamide treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients of the university hospital with a planed trabeculectomy in 3 to 4 weeks.
Criteria

Inclusion Criteria:

  • Patients with uncontrolled intraocular eye pressure
  • Patients with planed trabeculectomy in 3 to 4 weeks

Exclusion Criteria:

  • Patients not meeting the inclusion criteria
  • Patients with known intolerance to acetazolamide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274039


Locations
Germany
University of Cologne
Cologne, Germany, 50924
Sponsors and Collaborators
University of Cologne

ClinicalTrials.gov Identifier: NCT01274039     History of Changes
Other Study ID Numbers: AcetazolamideTrialCologne
First Posted: January 11, 2011    Key Record Dates
Last Update Posted: April 15, 2013
Last Verified: April 2013

Additional relevant MeSH terms:
Acetazolamide
Anticonvulsants
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs